CANADA LIFE ASSURANCE Co Sells 503 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

CANADA LIFE ASSURANCE Co decreased its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 0.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,943 shares of the biotechnology company’s stock after selling 503 shares during the period. CANADA LIFE ASSURANCE Co owned 0.08% of Sarepta Therapeutics worth $9,217,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. World Investment Advisors LLC acquired a new position in shares of Sarepta Therapeutics during the 3rd quarter worth about $2,418,000. Tidal Investments LLC boosted its stake in shares of Sarepta Therapeutics by 91.2% during the 3rd quarter. Tidal Investments LLC now owns 5,634 shares of the biotechnology company’s stock worth $704,000 after acquiring an additional 2,688 shares during the period. Garden State Investment Advisory Services LLC acquired a new position in shares of Sarepta Therapeutics during the 3rd quarter worth approximately $2,115,000. GAMMA Investing LLC raised its stake in Sarepta Therapeutics by 27.7% in the 4th quarter. GAMMA Investing LLC now owns 854 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 185 shares during the period. Finally, Everence Capital Management Inc. bought a new position in Sarepta Therapeutics during the fourth quarter worth $344,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Insider Buying and Selling

In related news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 7.70% of the stock is owned by company insiders.

Analyst Ratings Changes

SRPT has been the topic of a number of recent research reports. Royal Bank of Canada lowered Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their target price for the stock from $161.00 to $87.00 in a research note on Monday, March 31st. Morgan Stanley dropped their target price on Sarepta Therapeutics from $196.00 to $182.00 and set an “overweight” rating for the company in a report on Friday, April 11th. Scotiabank decreased their price target on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating on the stock in a research note on Thursday, March 20th. Needham & Company LLC dropped their price objective on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a “buy” rating for the company in a research note on Thursday, April 3rd. Finally, Wells Fargo & Company started coverage on shares of Sarepta Therapeutics in a research report on Friday, April 11th. They set an “overweight” rating and a $115.00 target price on the stock. Six equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $158.70.

Sarepta Therapeutics Price Performance

Shares of Sarepta Therapeutics stock opened at $55.23 on Tuesday. The stock has a market cap of $5.36 billion, a P/E ratio of 44.18 and a beta of 0.93. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The stock’s fifty day moving average is $81.12 and its 200 day moving average is $107.25. Sarepta Therapeutics, Inc. has a one year low of $48.01 and a one year high of $173.25.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.